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Our understanding of congenital infections is based on prospective studies of women infected in 
pregnancy.  The European Union has funded three consortia to study Zika virus (ZIKV), each including 
a prospective study of pregnant women.  Another has been funded by National Institutes of Health.  
This personal view sets out the study designs required to research ZIKV, and questions whether 
funding academics in the EU and US to work with collaborators in outbreak areas is an effective 
strategy. Three years after the 2015-2016 outbreaks, these collaborations have taught us little about 
ZIKV vertical transmission. In the time taken to approve funding, agree contracts, secure ethics 
approval, and equip laboratories, Zika had largely disappeared. By contrast, prospective studies 
based on local surveillance and standard of care (SOC) protocols have already provided valuable 
data. Threats to fetal and child health pose new challenges for global preparedness requiring 
support for the design and implementation of locally appropriate protocols. These can answer the 
key questions earlier and at lower cost. Local protocols can also provide a framework for 
recruitment of unexposed controls required to study less specific outcomes. Other priorities include 
accelerated development of non-invasive tests, and longer-term storage of neonatal and antenatal 
samples to facilitate retrospective reconstruction of cohort studies. 
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Past epidemics have triggered global initiatives to strengthen preparedness against emerging 
infectious disease threats, focusing on surveillance, detection and outbreak containment.1–4 It has 
been recognized that the higher risks faced by pregnant women and their infants during epidemics 
have often been overlooked within global preparedness frameworks,5,6  but emerging infections with 
teratogenic effects pose an entirely new set of challenges, particularly around research 
preparedness. 
The Zika virus (ZIKV) epidemic in 2015/2016, following the re-emergence of ZIKV in Asia and the 
Pacific in 20137, was unexpected.4 During the outbreak in Brazil from 20158,9, detection of babies 
with microcephaly and other abnormalities10,11 led to the identification of ZIKV as a teratogen, as 
seen for other congenital infections such as rubella or cytomegalovirus (CMV), but not previously 
observed for arboviruses.  The Pan-American Health Organization issued an Epidemiological Alert in 
May 201512 and WHO declared a Public Health Emergency of International Concern in February 
2016.13 The need for a coordinated research response was recognized quickly. The Global Research 
Collaboration for Infectious Disease Preparedness was engaged (www.glopid-r.org), and the 
European Commission (EC) issued a call for research and preparedness activities. The three EC 
consortia (Zika-PLAN (zikaplan.tghn.org/),14 ZIKAlliance (zikalliance.tghn.org), and ZIKAction 
(zikaction.org/)) are multi-disciplinary programmes, each including prospective vertical transmission  
cohort studies. In the US, the National Institutes for Health launched the ZIP (Zika in Pregnancy) 
Study (clinicaltrials.gov/ct2/show/NCT02856984). These projects have multiple field sites in the 
Caribbean, and Central and South America. 
Over three years since the Zika alerts were issued several important prospective vertical 
transmission studies have been published,15–18 but none from these externally-funded programmes.  
ZIKAlliance has pointed to “familiar barriers”, citing delays in the funding process and ethical 
approvals, and diagnostic challenges.19 They have argued for a “permanent … research capacity” 
with structured funding for a rapid response infrastructure. 
In this personal view, we explain why prospective studies to investigate Zika VT require particular 
design features, and consider other ways in which such studies could be originated and set in 
motion. Should it be the traditional pattern whereby Western academics are granted funds to work 
with research collaborators in affected areas, or can prospective studies be built onto appropriately 






Role of prospective cohort studies in understanding vertical transmission 
Understanding of congenital infections, such as rubella, CMV, toxoplasmosis, hepatitis C virus (HCV) 
and HIV, has been based largely on prospective cohort studies of pregnant women and their 
children.20–24  Pregnancies at risk are identified by screening women for markers of the relevant 
pathogen, and then followed forward with a more intensive care protocol, the outcome of 
pregnancy is recorded, and the newborn tested for infection acquired in utero or intrapartum.  
The protocol for identifying pregnancies at risk depends on the pathogen. With chronic infections, 
such as HIV and HCV, IgG antibody testing identifies pregnancies at risk.24,25 With toxoplasmosis the 
fetus is at risk only following primary infection in pregnancy, with at-risk pregnancies identified by 
repeat serological testing of susceptible (IgG-negative) women. This protocol would be less effective 
in detecting pregnancies at risk of congenital CMV, where non-primary infections also pose a risk.26  
The key property of the prospective cohort design is that it is women who are recruited, as early as 
possible before delivery, not the babies. Otherwise there is a risk of selectively recruiting 
pregnancies with adverse outcomes.  Ascertainment of infection in pregnancy should therefore pre-
date, or at least be independent of, any examination of the fetus (e.g. ultrasound scan) or newborn.  
Prospective studies aim to estimate the vertical transmission rate - the probability that the 
fetus/newborn is infected, given an infected mother. In classic studies of HIV,27,28 CMV29 and 
toxoplasmosis,22,30,31 the second key parameter is the rate of adverse outcomes in vertically-infected 
infants (Table 1). With less specific outcomes, uninfected infants of women infected during 
pregnancy constitute a control group (Control group 1 in Table 1).32,33 Infants of unexposed women, 
who have not been infected in pregnancy, can form a second control group (Table 1)34;  this is not 
routinely included in many prospective studies, but essential to study outcomes resulting directly 
from maternal infection, without the infection crossing to the fetus. Examples are prematurity, low 
birthweight and miscarriage, which have been reported with dengue,35 malaria36 and other 
infections.37  
 
The prospective study design as applied to Zika 
Applying the prospective design to ZIKV is not straightforward. Firstly, only a few of the components 
of Congenital Zika Syndrome (CZS) are specific to ZIKV and some require intensive investigation to 
detect.38 A control group is therefore essential. Second, PCR+ or IgM+ findings in newborn samples 
confirm congenital infection, but these markers are absent in a high proportion of CZS cases,39,40 




transient viremia in fetal blood, accompanied by post mortem isolation of ZIKV from brain tissue,42 
suggest that the virus can infect the fetus, causing serious damage but then clearing without leaving 
an immunological trace.  As presence or absence of congenital infection cannot be reliably 
established, a control Group 1 cannot be identified, and unexposed women and their offspring 
(Control Group 2) are required (Table 1). 
Identifying maternal infection in pregnancy (MIP) is also difficult with ZIKV. While MIP can be 
confirmed by PCR RNA, even the most intense PCR-based screening programme is likely to miss 
cases of MIP because most ZIKV infections are asymptomatic, and the PCR response may last no 
more than 7 days.43 Thus, failure to detect ZIKV RNA does not demonstrate “No MIP”. An IgG 
negative test in a woman at delivery is suggestive of No MIP, but little is known about ZIKV serology 
dynamics. In any case, this marker would only be useful in Zika-naïve populations exposed over a 
short period. Seroconversion is a reliable indicator of MIP if cross-reactions to other flavivirus 
antibody can be excluded.44 Tests of recent infection such as IgM, IgG3, or avidity assays have poor 
specificity, and even if cross-reactions are ruled out, may only reflect an infection that cleared 
before pregnancy.45  Probably, the best classification of maternal infection that can be achieved is 
likely to be along the lines of:  confirmed, suspected, and no evidence of MIP (although tested).  
 
Standard of care protocols for women exposed to Zika in pregnancy 
Recruitment into a formal prospective study requires informed consent to investigations that would 
not ordinarily be carried out under a SOC protocol. The question for study designers is therefore: 
what additional investigations are required, and in which patients, that are not already specified for 
SOC?  
Most countries in Latin America and the Caribbean made ZIKV a notifiable disease, creating a de 
facto surveillance system in which (symptomatic) pregnant women could be referred into a protocol 
for care in pregnancy. Early protocols in affected countries were therefore restricted to women with 
symptoms in pregnancy (Table 2). Later, in better-resourced settings, testing was extended to all 
pregnant women exposed to the outbreak, for example based on repeat serology.46 The current CDC 
protocol specifies 3 PCR tests through pregnancy. However, the key issue is whether the SOC 
provides for testing for congenital infection and follow-up of all newborns delivered to women with 
a confirmed infection in pregnancy, or only if there are congenital abnormalities (Table 2). Guidance 
from the Brazilian Ministry of Health has followed the latter course, in common with May 2016 
guidelines issued by WHO.47 The four prospective studies funded through international 




The response of WHO to ZIKV has been confused. Like the earlier CDC guidance,48 WHO 
recommended testing of women reporting symptoms with additional ultrasound to identify fetal 
malformations.  WHO argued against testing asymptomatic women, even in areas of high ZIKV 
incidence, as it failed on three of the Wilson & Junger screening criteria:49   poorly understood 
natural history ,  lack of effective treatment, and  low specificity of  diagnostic tests. But it is unclear 
why these criteria would not also rule out testing symptomatic women. On the other hand, the 
design of SOC and prospective study protocols alike must be sensitive to the cultural, religious, and 
medico-legal context: in some countries a confirmed diagnosis of ZIKV in pregnancy may be of little 
benefit to the mother, and could even lead to harm.50 In such circumstances protocols that go 
beyond multiple uterine  ultrasound may not be feasible.  
More critically, the WHO protocol47 made no provision for laboratory testing and follow-up of infants 
of women with confirmed or suspected ZIKV in pregnancy, unless congenital anomalies were 
present. Remarkably, positive ZIKV results in pregnancy are described as “false positives” if not 
resulting in microcephaly. WHO also recommended TORCH testing of neonates born to women with 
suspected ZIKV in pregnancy, but no tests for congenital ZIKV.51 WHO guidance may have 
discouraged some Latin American countries from adopting SOCs that would have provided 
appropriate care to families at risk, and which - as we show below - would concurrently have 
generated prospective study data on a very large scale.  
 
Prospective studies based on surveillance and SOC for Zika in pregnancy.  
During a ZIKV outbreak, pregnant women can be referred into a SOC protocol in two ways: either 
through a ZIKV surveillance system, if they have symptoms; or through repeat serological or 
virological testing offered by a maternity care provider. Once an SOC is operational, it inevitably 
generates cohorts of women with confirmed or suspected ZIKV in pregnancy.  A “prospective study” 
is therefore generated simply by carrying out SOC investigations and recording results. All the 
prospective studies published so far (Table 4) have been generated in this way.  
Equally, the same SOC protocols also generate unexposed controls groups (Control Group 2), at least 
to the extent that this is possible for ZIKV. Thus, some studies have reported outcomes in women 
who were PCR negative in pregnancy, interpretable as “No evidence of infection in pregnancy” 
(Table 4). However, detailed imaging, testing and follow-up of apparently healthy newborns born to 
women without evidence of MIP is explicitly ruled out in CDC guidelines,52 and is likely to require 
informed consent in any jurisdiction. It is at this point that a formal prospective study can go further 




their newborns. However, the identification of these infants, and ethical approval and logistics for 
follow-up, will be facilitated if their mothers are already part of a SOC protocol for ZIKV-exposed 
pregnant women. Follow-up of healthy children with no evidence of MIP raises some specific 
problems, which we return to below.  
Table 4 illustrates that prospective studies based on local SOCs are a viable alternative to 
collaborative projects funded through US or EC partners (Table 3), even in the absence of funding.16 
In the US, pregnancy outcomes in women potentially ZIKV-exposed and under the CDC protocol are 
recorded in the US Zika Pregnancy Register (USZPR). This has documented serious brain 
abnormalities with or without microcephaly in 6% to 15% of pregnancies with confirmed infection, 
with higher rates following first trimester infection.53–55  The authors acknowledge that these are 
likely to be over-estimates, as USZPR includes pregnancies in which Zika involvement was recognized 
retrospectively, following detection of anomalies on routine imaging, or at delivery.  
Such registers represent a third, and massively under-exploited way of generating prospective data 
on ZIKV in pregnancy. They can either recruit directly into prospective studies,56,57 or be  converted  
into prospective cohort studies retrospectively, by checking the dates of maternal tests relative to 
delivery, and removing mother-child pairs in which infection in pregnancy was retrospectively 
ascertained. Just such a retrospective reconstruction of a prospective cohort based on the USZPR 
was conducted in New York City,58 reporting markers of congenital infection in 11% and 7% of 
infants of mothers with “confirmed” and “probable” infection in pregnancy respectively (Table 4). 
  
Other opportunities for retrospective reconstruction of prospective studies 
SOC protocols that provide for infant testing and follow-up cannot be established immediately in the 
context of outbreaks that emerge rapidly and without warning. There will therefore always be a 
need for retrospective reconstructions. One option is to reconstruct prospective studies from 
surveillance records of pregnant women who reported symptoms and were tested.  
With hindsight, it now seems remarkable that in many countries these pregnancies were not 
referred to ZIKV-related care protocols in maternity hospitals for additional investigations and infant 
follow-up.  This should remind us that whatever protocols are in place, there may be insufficient 
resources for laboratory infrastructure and follow-up. However, this process can be carried out 
retrospectively as a review of maternity and delivery records. Consent could also be sought for 




An interesting addition to retrospective review would be to use residual samples routinely collected 
for newborn sickle cell and/or metabolic screening, as dried blood spots. Many countries in Latin 
America and the Caribbean have routine newborn screening in national, regional and hospital 
laboratories.59  Newborn dried blood spots have been tested in retrospectively reconstructed cohort 
studies of congenital infections60 but also in irreversibly anonymized studies retaining demographic 
information.61,62 Stored residual newborn dried blood spots could be tested for ZIKV RNA and IgM, 
retaining information on confirmed or suspected maternal ZIKV infection, and trimester in which 
symptoms occurred. Laboratory markers cannot be found in a proportion of congenital infection,41,42 
but studies would set a lower limit on the vertical transmission rate.  A sample of newborns of 
women with no evidence of Zika could also be included, as well as randomly selected controls whose 
mothers were not notified to surveillance.  
A second potential approach to reconstruct prospective studies post-epidemic is the use of stored 
samples collected during routine antenatal care whilst the outbreak was ongoing. These could be 
tested for markers of infection; confirmed and suspected cases, plus a sample of those with “No 
Evidence of MIP”, could again be entered into a record review of pregnancy and neonatal outcomes 
as above, with the option of obtaining consent for pediatric follow-up, and testing of stored residual 
newborn screening samples. Joint testing of linked anonymized antenatal and neonatal samples 
creates many further opportunities for large-scale reconstruction of incidence in pregnant women 
and vertical transmission, although is logistically more complex. 
These designs could be applied now to study the 2015-16 Zika outbreak, but they have a wider 
significance. There will always be a role for retrospectively reconstructed cohort studies in future 
outbreaks of pathogens that affect fetal health, especially when no clear diagnostic pathway, or 
even the pathogen, is identified until later. Such studies may be especially valuable in countries 
where medical, religious, legal or cultural constraints limit the benefit of a prospective diagnosis of 
ZIKV in pregnancy. There are logistic requirements: if conducted prospectively, studies based on 
surveillance reports require only coordination between the surveillance centre, the relevant 
laboratory and the maternity hospital.15,17,18 However, in a retrospective design, these three sets of 
patient records have to be linked. This can be done using names, addresses, and dates of birth, but 
record linkage can be greatly facilitated by having unique common identifier, such as the mother’s 
national security number, on all records, including those of the infant.  
Retrospective designs require neonatal and antenatal samples to be stored for longer, which has a 
cost. Resources could be conserved by focusing on a small number of maternity hospitals serving 




Retrospective studies including “control” mother-child pairs may also require consent, which could 
perhaps be obtained on a universal basis during an outbreak. 
 
Role of international agencies and funders in global preparedness 
Only prospective studies can fully answer the key scientific and public health questions around ZIKV 
infection in pregnancy and its consequences, ideally including an unexposed control group. We have 
argued that SOC protocols for pregnant women provide a feasible approach, allowing autonomy of 
local institutional review boards, and ensuring access to the relevant diagnostics and to locally 
trained research and nursing staff integrated within the health care system. This resolves the delays 
and barriers19 that confront prospective studies established by externally-funded researchers (ethics 
approvals, creation of data collection systems and laboratory infrastructure).  Furthermore, 
externally-originated research protocols may do little to foster global preparedness if the 
infrastructure is unsupported once the project ends.  
One of the difficulties in studying outcomes of ZIKV in pregnancy is testing and follow-up of healthy 
children, especially when maternal infection is not apparent. It is recognized that global 
preparedness demands much faster development of diagnostics,63 but the particular need for non-
invasive tests may not have been appreciated. Capillary blood samples collected by heel prick are 
well accepted, widely used with rapid diagnostic tests (RDTs) and can be dried and stored long-term. 
Oral fluid samples contain the same antibody pattern as serum and are used for measles and rubella 
case-based surveillance,64,65 for HIV RDTs,66 and extensively for virus detection by PCR. Throat swabs 
are used for diagnosis of congenital CMV.67  
We believe that global preparedness must focus more on the care of pregnant women and their 
children, with the primary task being the development of culturally sensitive SOC protocols that are 
appropriate to settings and resources available, backed up by assistance in implementing them, 
including approaches to data capture, recording and linkage. These SOCs represent de facto 
prospective studies that will answer the key research questions more rapidly than  internationally-
led research studies. Furthermore, prospective studies can be reconstructed on a very large scale, 
with appropriate filtering out of retrospectively-ascertained maternal infection, from registers 
recording outcomes under SOC. For more subtle outcomes, informed consent would be needed to 
follow-up unexposed “control” infants, but this can be built onto SOC protocols.  
Strengthened surveillance is a key component of preparedness:6 a focus on pregnancy would 
prioritize surveillance for stillbirths, neonatal mortality, congenital malformations, auditory and 




emerges with potential for congenital infection, international agencies should devise mechanisms 
for accelerated development of non-invasive diagnostics, and promote facilities for longer-term 
storage of routinely collected antenatal and neonatal samples, which can be linked to maternity and 
pediatric records. No matter how rapid the response to an emerging pathogen, retrospective studies 
based on stored samples will always be needed.  
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Table 1. Design of a prospective vertical transmission study. The table shows cell frequency counts 
a,b…f of birth outcomes broken down by congenital infection status, presence or absence of adverse 
outcomes, and maternal infection status. The Vertical Transmission rate is estimated by 
(a+b)/(a+b+c+d). The rate of adverse outcomes conditional on congenital infection is a/(a+b).  For 
less specific adverse outcomes this can be compared with the rate of outcomes in newborns with no 
congenital infection, c/(c+d), whose mothers were infected in pregnancy (Control Group 1). An 
overall adverse event rate can be estimated, (a+c)/(a+b+c+d), pooling congenital infection and No 
congenital infection. Follow-up of births where there has been no maternal infection in pregnancy 
(MIP) represent a second control group (Control Group 2), with a rate of adverse outcomes, e/(e+f). 
In the absence of clear diagnostic criteria for congenital infection, as with ZIKV, this second control 
group is needed.  
Some cells have zeros as there can be no congenital infection without maternal infection in 
pregnancy. 
 
 Maternal Infection in Pregnancy (MIP) 
Status 





















Adverse outcomes a 0 
No Adverse outcomes b 0 
No CI 
Adverse outcomes c E 






Table 2.  Standard protocols of care for women exposed to Zika outbreaks 
State Date Provision for screening women 
potentially exposed during 
pregnancy 
Care of newborn mother 
with confirmed ZIKV in 
pregnancy 
USA  January 201648 PCR, IgM if symptomatic, 
additional U/S if asymptomatic 
Laboratory testing for 
congenital ZIKV, clinical 
follow-up 
Brazil January 201668 Testing and U/S in symptomatic Follow-up if microcephaly  
France  January 2016 69 PCR, IgM additional U/S if 
symptomatic 
Laboratory testing for 
congenital ZIKV, clinical 
follow-up 
France April 201670 PCR, IgM testing regardless of 
symptoms 
Laboratory testing, clinical 
follow-up 
WHO May 201647 Testing and U/S if symptomatic Follow-up if microcephaly  
WHO August 201651 Not applicable TORCH screen, but no tests 
for Congenital ZIKV 
Brazil November 201671 Testing and U/S if symptomatic Follow-up if symptoms of 
ZIKA in first 3 years 
USA  July 201772 3 PCR tests, additional U/S, 
regardless of symptoms 
Laboratory testing for 
congenital ZIKV, clinical 
follow-up 
Spain  April 201773 PCR, IgM and IgG regardless of 
symptoms, alongside U/S; if IgG(+) 
then PRNT-ZIKV 
Laboratory testing for 
congenital ZIKV and clinical 
follow-up for all born to 
ZIKV-infected mothers 







Table 3. Protocols of four international collaborative prospective studies, funded through US or EU 
partners 
 
Study Funder Provision for screening women 
potentially exposed during 
pregnancy 
Care of newborn of mother 




Repeat serological and PCR tests Laboratory testing for 




Repeat serological tests Laboratory testing for 












Repeat PCR tests Laboratory testing for 






Table 4. Prospective studies published before April 2019: method of recruitment, cohorts followed, prevalence of adverse outcomes and of markers of 
congenital infection (CI).  
Region Recruitment Cohorts reported Adverse Outcomes, % Markers 
of CI, % 
Brazil18 Rash in pregnancy, 
dengue surveillance 
programme 
1. Confirmed MIP (n=134) 
2. No Evidence of MIP (n=73) 




Texas, USA56 Prospective USZPR 1. Confirmed or probable MIP (n=28) 





French Guiana46 Three PCR tests on all 
pregnant women 
1. Confirmed MIP (n=301) 
2. No Evidence of MIP (n=399) 




French Guiana 74 Three PCR tests on all 
pregnant women 
1. Confirmed MIP (n=291) 4% “Severe complications” 35% 
Martinique & Guadeloupe  15 ZIKV Surveillance, 
symptomatic women 
1. Confirmed MIP (n=555) 10% “Neurological and 
ocular defects” 
NR 
Colombia75 National surveillance 1. ZIKV Symptoms in pregnancy, 3rd 
trimester (n=c.570) 
0% “microcephaly <3SD or 
brain abnormalities 
NR 
New York City, USA 58 Retrospective 
reconstruction USZPR, 
1. Confirmed (n=80) 





Brazil 17 Symptoms of ZIKV in 
pregnancy 
1. Confirmed MIP (n=57) 28% “Adverse outcomes” 26% 
Barcelona57  ZIKV surveillance 
travellers 
1. Confirmed MIP (n=9) 
2. Probable MIP (n=62) 










1 Kluberg SA, Mekaru SR, McIver DJ, et al. Global capacity for emerging infectious disease 
detection, 1996–2014. Emerg Infect Dis 2016; 22: e1–9. 
2 Sands P, Mundaca-Shah C, Dzau VJ. The Neglected Dimension of Global Security — A 
Framework for Countering Infectious-Disease Crises. N Engl J Med 2016; 374: 1281–7. 
3 Oppenheim B, Gallivan M, Madhav NK, et al. Assessing global preparedness for the next 
pandemic: Development and application of an Epidemic Preparedness Index. BMJ Glob Heal 
2019; 4: 1–9. 
4 Musso D, Bossin H, Mallet HP, et al. Zika virus in French Polynesia 2013–14: anatomy of a 
completed outbreak. Lancet Infect Dis 2018; 18: e172–82. 
5 Haddad LB, Horton J, Ribner BS, Jamieson DJ. Ebola Infection in Pregnancy: A Global 
Perspective and Lessons Learned. Clin Obstet Gynecol 2018; 61: 186–96. 
6 The PREVENT Working Group. Pregnant women & vaccines against emerging epidemic 
threats: Ethics Guidance for Preparedness, Research, and Response. 2018. 
7 Roth A, Mercier A, Lepers C, et al. Concurrent outbreaks of dengue, chikungunya and zika 
virus infections null An unprecedented epidemic wave of mosquito-borne viruses in the 
Pacific 2012null2014. Eurosurveillance 2014; 19: 1–8. 
8 Campos GS, Bandeira AC, Sardi SI. Zika Virus Outbreak, Bahia, Brazil. Emerg Infect Dis 2015; 
21: 1885–6. 
9 Pan American Health Organization / World Health Organization. Zika - Epidemiological 
Update, 26 January 2017. 2017. 
10 França GVA, Schuler-Faccini L, Oliveira WK, et al. Congenital Zika virus syndrome in Brazil: a 
case series of the first 1501 livebirths with complete investigation. Lancet 2016; 388: 891–7. 
11 Calvet G, Aguiar RS, Melo ASO, et al. Detection and sequencing of Zika virus from amniotic 
fluid of fetuses with microcephaly in Brazil: a case study. Lancet Infect Dis 2016; 16: 653–60. 
12 PAHO, WHO. Epidemiological Alert: Zika virus infection. 2015. DOI:10.1111/1469-0691.12707. 
13 Gulland A. Zika virus is a global public health emergency, declares WHO. BMJ 2016; 352: i657. 
14 Wilder-Smith A, Preet R, Renhorn KE, et al. ZikaPLAN: Zika Preparedness Latin American 
Network. Glob Health Action 2017; 10: 1398485. 
15 Hoen B, Schaub B, Funk AL, et al. Pregnancy Outcomes after ZIKV Infection in French 
Territories in the Americas. N Engl J Med 2018; 378: 985–94. 
16 Pomar L, Vouga M, Lambert V, et al. Maternal-fetal transmission and adverse perinatal 
outcomes in pregnant women infected with Zika virus: Prospective cohort study in French 
Guiana. BMJ 2018; 363: k4431. 
17 Nogueira ML, Nery Júnior NRR, Estofolete CF, et al. Adverse birth outcomes associated with 
Zika virus exposure during pregnancy in São José do Rio Preto, Brazil. Clin Microbiol Infect 
2018; 24: 646–52. 
18 Brasil P, Pereira J, Moreira E, et al. Zika Virus Infection in Pregnant Women in Rio de Janeiro. 
N Engl J Med 2016; 56: 1024–5. 
19 Koopmans M, de Lamballerie X, Jaenisch T, et al. Familiar barriers still unresolved—a 
perspective on the Zika virus outbreak research response. Lancet Infect. Dis. 2019; 19: e59–
62. 
20 Stagno S, Pass RF, Cloud G, et al. Primary cytomegalovirus infection in pregnancy. Incidence, 
transmission to fetus, and clinical outcome. JAMA 1986; 256: 1904–8. 
21 Peckham CS, Coleman JC, Hurley R, Kong Shin Chin, Henderson K, Preece PM. 




Lancet 1983; 321: 1352–5. 
22 Gras L, Gilbert RE, Ades AE, Dunn DT. Effect of prenatal treatment on the risk of intracranial 
and ocular lesions in children with congenital toxoplasmosis. Int J Epidemiol 2001; 30: 1309–
13. 
23 The SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group. Effectiveness of 
prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients’ data. 
Lancet 2007; 369: 115–22. 
24 Mok JQ, Giaquinto C, De Rossi A, Grosch-Wörner I, Ades AE, Peckham CS. Infants born to 
mothers seropositive for human immunodeficiency virus. Preliminary findings from a 
multicentre European study. Lancet (London, England) 1987; 1: 1164–8. 
25 Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: 
prospective study of risk factors and timing of infection in children born to women 
seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. Bmj 1998; 317: 
437–41. 
26 Ahlfors K, Ivarsson SA, Johnsson T, Svanberg L. Primary and Secondary maternal 
cytomegalovirus infections and their relation to congenital infection: Analysis of Maternal 
Sera. Acta Pædiatrica 1982; 71: 109–13. 
27 Mandelbrot, Mayaux, Bongain, et al. Obstetric factors and mother-to-child transmission of 
human immunodeficiency virus type 1: The French perinatal cohorts. Am J Obstet Gynecol 
1996; 175: 661–7. 
28 Dunn DT, Ades AE. Estimating the HIV Vertical Transmission Rate and the Pediatric AIDS 
Incubation Period from Prospective Data AU. J Am Stat Assoc 1996; 91: 935–43. 
29 Stagno S, Pass RF, Dworsky ME, et al. Congenital Cytomegalovirus Infection: The relative 
importance of primary and recurrent maternal infection. N Engl J Med 1982; 306: 945–9. 
30 Gilbert RE, Gras L, Wallon M, Peyron F, Ades AE, Dunn DT. Effect of prenatal treatment on 
mother to child transmission of Toxoplasma gondii: Retrospective cohort study of 554 
mother-child pairs in Lyon, France. Int J Epidemiol 2001; 30: 1303–8. 
31 SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group. Effectiveness of 
prenatal treatment for congenital toxoplasmosis: A meta-analysis of individual patients’ data. 
Lancet. 2007; 62: 302–4. 
32 Preece PM, Blount JM, Glover J, Fletcher GM, Peckham CS, Griffiths PD. The consequences of 
primary cytomegalovirus infection in pregnancy. Arch Dis Child 1983; 58: 970–5. 
33 Townsend CL, Forsgren M, Ahlfors K, Ivarsson SA, Tookey PA, Peckham CS. Long-term 
outcomes of congenital cytomegalovirus infection in Sweden and the United Kingdom. Clin 
Infect Dis 2013; 56: 1232–9. 
34 Li XL, Wei HX, Zhang H, Peng HJ, Lindsay DS. A meta analysis on risks of adverse pregnancy 
outcomes in Toxoplasma gondii infection. PLoS One 2014; 9: 1–12. 
35 Paixão ES, Costa M da CN, Teixeira MG, et al. Symptomatic dengue infection during 
pregnancy and the risk of stillbirth in Brazil, 2006–12: a matched case-control study. Lancet 
Infect Dis 2017; 17: 957–64. 
36 Rijken MJ, McGready R, Boel ME, et al. Malaria in pregnancy in the Asia-Pacific region. Lancet 
Infect Dis 2012; 12: 75–88. 
37 Cardenas I, Means RE, Aldo P, et al. Viral Infection of the Placenta Leads to Fetal 
Inflammation and Sensitization to Bacterial Products Predisposing to Preterm Labor. J 
Immunol 2010; 185: 1248–57. 
38 Moore CA, Staples JE, Dobyns WB, et al. Characterizing the pattern of anomalies in congenital 




39 van der Linden V, Pessoa A, Dobyns W, et al. Description of 13 Infants Born During October 
2015–January 2016 With Congenital Zika Virus Infection Without Microcephaly at Birth — 
Brazil. Morb Mortal Wkly Rep 2016; 65: 1343–8. 
40 de Araújo TVB, Ximenes RA de A, Miranda-Filho D de B, et al. Association between 
microcephaly, Zika virus infection, and other risk factors in Brazil: Final report of a case-
control study. Lancet Infect Dis 2017; 3099: 1–9. 
41 Rodó C, Suy A, Sulleiro E, et al. In utero negativization of Zika virus in a foetus with serious 
central nervous system abnormalities. Clin Microbiol Infect 2018; 24: 549.e1-549.e3. 
42 Schaub B, Vouga M, Najioullah F, et al. Analysis of blood from Zika virus-infected fetuses: a 
prospective case series. Lancet Infect Dis 2017; 17: 520–7. 
43 Paz-Bailey G, Rosenberg ES, Doyle K, et al. Persistence of Zika Virus in Body Fluids — Final 
Report. N Engl J Med 2018; : NEJMoa1613108. 
44 Rabe IB, Staples JE, Villanueva J, et al. Interim Guidance for Interpretation of Zika Virus 
Antibody Test Results. MMWR Morb Mortal Wkly Rep 2016; 65: 543–6. 
45 Centers for Disease Control and Prevention. Prolonged IgM Antibody Response in People 
Infected with Zika Virus : Implications for Interpreting Serologic Testing Results for Pregnant. 
2017; : 5–7. 
46 Pomar L, Malinger G, Benoist G, et al. Association between Zika virus and fetopathy: a 
prospective cohort study in French Guiana. Ultrasound Obstet Gynecol 2017; 49: 729–36. 
47 World Health Organization. Pregnancy management in the context of Zika virus infection: 
Interim guidance update. 13 May 2016. 2016. 
48 Petersen EE, Meaney-Delman, D, Ellington SR, et al. Interim Guidelines for Pregnant Women 
During a Zika Virus Outbreak — United States, 2016. MMWR Morb Mortal Wkly Rep 2016; 65: 
1–4. 
49 Wilson JMG, Jugner G. Principles and Practice of Screening for Disease. Geneva, 1968 
DOI:10.3390/ijns3030023. 
50 Roa M. Zika virus outbreak: Reproductive health and rights in Latin America. Lancet 2016; 
387: 843. 
51 World Health Organization. Screening, assessment and management of neonates and infants 
with complications associated with Zika virus exposure in utero. 2016 
DOI:http://apps.who.int/iris/bitstream/10665/204475/1/WHO_ZIKV_MOC_16.3_eng.pdf?ua
=1. 
52 Adebanjo T, Godfred-Cato S, Viens L, et al. Update: Interim Guidance for the Diagnosis, 
Evaluation, and Management of Infants with Possible Congenital Zika Virus Infection — 
United States, October 2017. MMWR Morb Mortal Wkly Rep 2017; 66: 1089–99. 
53 Honein MA, Dawson AL, Petersen EE, et al. Birth defects among fetuses and infants of US 
women with evidence of possible zika virus infection during pregnancy. JAMA - J Am Med 
Assoc 2017; 317: 59–68. 
54 Reynolds M, Jones A, Petersen E, Lee E, Rice M, Bingham A. Vital Signs: Update on Zika Virus–
Associated Birth Defects and Evaluation of All U.S. Infants with Congenital Zika Virus Exposure 
— U.S. Zika Pregnancy Registry, 2016. Morb Mortal Wkly Rep 2017; 66: 366–73. 
55 Shapiro-Mendoza CK, Rice ME, Galang RR, et al. Pregnancy Outcomes After Maternal Zika 
Virus Infection During Pregnancy — U.S. Territories, January 1, 2016–April 25, 2017. MMWR 
Morb Mortal Wkly Rep 2017; 66: 615–21. 
56 Adhikari EH, Nelson DB, Johnson KA, et al. Infant outcomes among women with Zika virus 
infection during pregnancy: results of a large prenatal Zika screening program. Am J Obstet 




57 Rodó C, Suy A, Sulleiro E, et al. Pregnancy outcomes after maternal Zika virus infection in a 
non-endemic region: prospective cohort study. Clin Microbiol Infect 2019. 
DOI:10.1016/j.cmi.2019.02.008. 
58 Conners EE, Lee EH, Thompson CN, et al. Zika Virus Infection Among PregnantWomen and 
Their Neonates in NewYork City, January 2016–June 2017. Obs Gynecol 2018; 132: 487–95. 
59 Therrell BL, Padilla CD, Loeber JG, et al. Current status of newborn screening worldwide: 
2015. Semin Perinatol 2015; 39: 171–87. 
60 Korndewal MJ, Vossen ACTM, Cremer J, et al. Disease burden of congenital cytomegalovirus 
infection at school entry age: Study design, participation rate and birth prevalence. Epidemiol 
Infect 2016; 144: 1520–7. 
61 Ades AE, Walker J, Botting B, Parker S, Cubitt D, Jones R. Effect of the worldwide epidemic on 
HIV prevalence in the United Kingdom: Record linkage in anonymous neonatal 
seroprevalence surveys. AIDS 1999; 13: 2437–43. 
62 Carnicer-Pont D, Montoliu A, Marín JL, et al. Twenty years trends and socio-demographic 
characteristics of HIV prevalence in women giving birth in Catalonia (Spain). Gac Sanit 2015; 
29: 347–52. 
63 Peeling RW, Murtagh M, Olliaro PL. Epidemic preparedness: why is there a need to accelerate 
the development of diagnostics? Lancet Infect Dis 2018; 3099: 1–7. 
64 Manikkavasagan G, Bukasa A, Brown KE, Cohen BJ, Ramsay ME. Oral fluid testing during 10 
years of rubella elimination, England and Wales. Emerg Infect Dis 2010; 16: 1532–8. 
65 Jin L, Vyse A, Brown DWG. The role of RT-PCR assay of oral fluid for diagnosis and surveillance 
of measles, mumps and rubella. Bull. World Health Organ. 2002; 80: 76–7. 
66 Belete W, Deressa T, Feleke A, et al. Evaluation of diagnostic performance of noninvasive HIV 
self-testing kit using oral fluid in Addis Ababa, Ethiopia: A facility-based cross-sectional study. 
PLoS One 2019; 14: 1–10. 
67 Roth DAE, Lubin D, Kuint J, et al. Contribution of targeted saliva screening for congenital 
CMV-related hearing loss in newborns who fail hearing screening. Arch Dis Child Fetal 
Neonatal Ed 2017; 102: F519–24. 
68 Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Protocolo de atenção à saúde e 
resposta à ocorrência de microcefalia relacionada à  infecção pelo vírus Zika. 2016. 
69 Haut Conseil de la Santé Publique. Avis relatif à l’actualisation de l’avis du HCSP du 28 juillet 
2015 relatif à la prise en charge médicale des personnes atteintes par le virus Zika. 2016; : 1–
27. 
70 Collège National de Gynécologues at Obstétricens Français. Virus ZIKA Et femme enceinte ou 
en âge de procréer. 2014; : 1–6. 
71 BRASIL, Ministério da Saúde. Diretrizes de estimulação precoce Crianças de zero a 3 anos com 
Atraso no Desenvolvimento Neuropsicomotor Decorrente de Microcefalia. Ministério da 
Saúde Secr Atenção à Saúde 2016; : 123. 
72 Oduyebo T, Polen KD, Walke HT, et al. Update: Interim Guidance for Health Care Providers 
Caring for Pregnant Women with Possible Zika Virus Exposure — United States (Including U.S. 
Territories), July 2017. MMWR Morb Mortal Wkly Rep 2017; 66: 781–93. 
73 Subdirecció General de Vigilància i Resposta a Emergències de Salut Pública. Generalitat de 
Catalunya. Protocol d’actuació davant de casos de febre vírica de Zika en l’àmbit obstètric i 
pediàtric de Catalunya. Barcelona Agència Salut Pública Catalunya 2016. 
74 Pomar L, Vouga M, Lambert V, et al. Maternal-fetal transmission and adverse perinatal 
outcomes in pregnant women infected with Zika virus: Prospective cohort study in French 




75 Pacheco O, Beltrán M, Nelson CA, et al. Zika Virus Disease in Colombia — Preliminary Report. 





Researching Zika in pregnancy: lessons for global preparedness 
 
AE Ades PhD. Department of Population Health Science, University of Bristol Medical School, 38 
Whatley Road, Bristol BS8 2PS, United Kingdom 
Claire Thorne PhD, Population Policy and Practice Programme, University College London Great 
Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH, United Kingdom 
Antoni Soriano-Arandes PhD. Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital 
Universitari Vall d’Hebron, Vall d’Hebron Research Institute, Barcelona, Spain 
Catherine S Peckham MD. Population Policy and Practice Programme, University College London 
Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH, United 
Kingdom 
David W Brown PhD. Fundacão Oswaldo Cruz, Flavivirus Reference Laboratory, Rio de Janeiro, Brazil  
Daniel Lang PhD. Fondazione Penta Onlus. Rua Correia de Lemos, 684 #142. São Paulo, SP, Brazil 
J Glenn Morris MD. Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA 
Celia D C Christie MD. Department of Child and Adolescent Health, University of the West Indies, 
Mona Campus, Kingston, Jamaica. 
Carlo Giaquinto MD. Dipartimento di Salute della Donna e del Bambino, Università degli Studi 
di Padova, Via Giustiniani, 3 - 35128 Padova. Italy 
 
Corresponding author: 
AE Ades PhD. Department of Population Health Science, University of Bristol Medical School, 38 




Zika global prep rev3     November 28 2019 
  





Our understanding of congenital infections is based on prospective studies of women infected in 
pregnancy.  The European Union has funded three consortia to study Zika virus (ZIKV), each including 
a prospective study of pregnant women.  Another has been funded by National Institutes of Health.  
This personal view sets out the study designs required to research ZIKV, and questions whether 
funding academics in the EU and US to work with collaborators in outbreak areas is an effective 
strategy. Three years after the 2015-2016 outbreaks, these collaborations have taught us little about 
ZIKV vertical transmission. In the time taken to approve funding, agree contracts, secure ethics 
approval, and equip laboratories, Zika had largely disappeared. By contrast, prospective studies 
based on local surveillance and standard of care (SOC) protocols have already provided valuable 
data. Threats to fetal and child health pose new challenges for global preparedness requiring 
support for the design and implementation of locally appropriate protocols. These can answer the 
key questions earlier and at lower cost. Local protocols can also provide a framework for 
recruitment of unexposed controls required to study less specific outcomes. Other priorities include 
accelerated development of non-invasive tests, and longer-term storage of neonatal and antenatal 
samples to facilitate retrospective reconstruction of cohort studies. 
<208 words> 
 







Past epidemics have triggered global initiatives to strengthen preparedness against emerging 
infectious disease threats, focusing on surveillance, detection and outbreak containment.1–4 It has 
been recognized that the higher risks faced by pregnant women and their infants during epidemics 
have often been overlooked within global preparedness frameworks,5,6  but emerging infections with 
teratogenic effects pose an entirely new set of challenges, particularly around research 
preparedness. 
The Zika virus (ZIKV) epidemic in 2015/2016, following the re-emergence of ZIKV in Asia and the 
Pacific in 20137, was unexpected.4 During the outbreak in Brazil from 20158,9, detection of babies 
with microcephaly and other abnormalities10,11 led to the identification of ZIKV as a teratogen, as 
seen for other congenital infections such as rubella or cytomegalovirus (CMV), but not previously 
observed for arboviruses.  The Pan-American Health Organization issued an Epidemiological Alert in 
May 201512 and WHO declared a Public Health Emergency of International Concern in February 
2016.13 The need for a coordinated research response was recognized quickly. The Global Research 
Collaboration for Infectious Disease Preparedness was engaged (www.glopid-r.org), and the 
European Commission (EC) issued a call for research and preparedness activities. The three EC 
consortia (Zika-PLAN (zikaplan.tghn.org/),14 ZIKAlliance (zikalliance.tghn.org), and ZIKAction 
(zikaction.org/)) are multi-disciplinary programmes, each including prospective vertical transmission  
cohort studies. In the US, the National Institutes for Health launched the ZIP (Zika in Pregnancy) 
Study (clinicaltrials.gov/ct2/show/NCT02856984). These projects have multiple field sites in the 
Caribbean, and Central and South America. 
Over three years since the Zika alerts were issued several important prospective vertical 
transmission studies have been published,15–18 but none from these externally-funded programmes.  
ZIKAlliance has pointed to “familiar barriers”, citing delays in the funding process and ethical 
approvals, and diagnostic challenges.19 They have argued for a “permanent … research capacity” 
with structured funding for a rapid response infrastructure. 
In this personal view, we explain why prospective studies to investigate Zika VT require particular 
design features, and consider other ways in which such studies could be originated and set in 
motion. Should it be the traditional pattern whereby Western academics are granted funds to work 
with research collaborators in affected areas, or can prospective studies be built onto appropriately 






Role of prospective cohort studies in understanding vertical transmission 
Understanding of congenital infections, such as rubella, CMV, toxoplasmosis, hepatitis C virus (HCV) 
and HIV, has been based largely on prospective cohort studies of pregnant women and their 
children.20–24  Pregnancies at risk are identified by screening women for markers of the relevant 
pathogen, and then followed forward with a more intensive care protocol, the outcome of 
pregnancy is recorded, and the newborn tested for infection acquired in utero or intrapartum.  
The protocol for identifying pregnancies at risk depends on the pathogen. With chronic infections, 
such as HIV and HCV, IgG antibody testing identifies pregnancies at risk.24,25 With toxoplasmosis the 
fetus is at risk only following primary infection in pregnancy, with at-risk pregnancies identified by 
repeat serological testing of susceptible (IgG-negative) women. This protocol would be less effective 
in detecting pregnancies at risk of congenital CMV, where non-primary infections also pose a risk.26  
The key property of the prospective cohort design is that it is women who are recruited, as early as 
possible before delivery, not the babies. Otherwise there is a risk of selectively recruiting 
pregnancies with adverse outcomes.  Ascertainment of infection in pregnancy should therefore pre-
date, or at least be independent of, any examination of the fetus (e.g. ultrasound scan) or newborn.  
Prospective studies aim to estimate the vertical transmission rate - the probability that the 
fetus/newborn is infected, given an infected mother. In classic studies of HIV,27,28 CMV29 and 
toxoplasmosis,22,30,31 the second key parameter is the rate of adverse outcomes in vertically-infected 
infants (Table 1). With less specific outcomes, uninfected infants of women infected during 
pregnancy constitute a control group (Control group 1 in Table 1).32,33 Infants of unexposed women, 
who have not been infected in pregnancy, can form a second control group (Table 1)34;  this is not 
routinely included in many prospective studies, but essential to study outcomes resulting directly 
from maternal infection, without the infection crossing to the fetus. Examples are prematurity, low 
birthweight and miscarriage, which have been reported with dengue,35 malaria36 and other 
infections.37  
 
The prospective study design as applied to Zika 
Applying the prospective design to ZIKV is not straightforward. Firstly, only a few of the components 
of Congenital Zika Syndrome (CZS) are specific to ZIKV and some require intensive investigation to 
detect.38 A control group is therefore essential. Second, PCR+ or IgM+ findings in newborn samples 
confirm congenital infection, but these markers are absent in a high proportion of CZS cases,39,40 




transient viremia in fetal blood, accompanied by post mortem isolation of ZIKV from brain tissue,42 
suggest that the virus can infect the fetus, causing serious damage but then clearing without leaving 
an immunological trace.  As presence or absence of congenital infection cannot be reliably 
established, a control Group 1 cannot be identified, and unexposed women and their offspring 
(Control Group 2) are required (Table 1). 
Identifying maternal infection in pregnancy (MIP) is also difficult with ZIKV. While MIP can be 
confirmed by PCR RNA, even the most intense PCR-based screening programme is likely to miss 
cases of MIP because most ZIKV infections are asymptomatic, and the PCR response may last no 
more than 7 days.43 Thus, failure to detect ZIKV RNA does not demonstrate “No MIP”. An IgG 
negative test in a woman at delivery is suggestive of No MIP, but little is known about ZIKV serology 
dynamics. In any case, this marker would only be useful in Zika-naïve populations exposed over a 
short period. Seroconversion is a reliable indicator of MIP if cross-reactions to other flavivirus 
antibody can be excluded.44 Tests of recent infection such as IgM, IgG3, or avidity assays have poor 
specificity, and even if cross-reactions are ruled out, may only reflect an infection that cleared 
before pregnancy.45  Probably, the best classification of maternal infection that can be achieved is 
likely to be along the lines of:  confirmed, suspected, and no evidence of MIP (although tested).  
 
Standard of care protocols for women exposed to Zika in pregnancy 
Recruitment into a formal prospective study requires informed consent to investigations that would 
not ordinarily be carried out under a SOC protocol. The question for study designers is therefore: 
what additional investigations are required, and in which patients, that are not already specified for 
SOC?  
Most countries in Latin America and the Caribbean made ZIKV a notifiable disease, creating a de 
facto surveillance system in which (symptomatic) pregnant women could be referred into a protocol 
for care in pregnancy. Early protocols in affected countries were therefore restricted to women with 
symptoms in pregnancy (Table 2). Later, in better-resourced settings, testing was extended to all 
pregnant women exposed to the outbreak, for example based on repeat serology.46 The current CDC 
protocol specifies 3 PCR tests through pregnancy. However, the key issue is whether the SOC 
provides for testing for congenital infection and follow-up of all newborns delivered to women with 
a confirmed infection in pregnancy, or only if there are congenital abnormalities (Table 2). Guidance 
from the Brazilian Ministry of Health has followed the latter course, in common with May 2016 
guidelines issued by WHO.47 The four prospective studies funded through international 




The response of WHO to ZIKV has been confused. Like the earlier CDC guidance,48 WHO 
recommended testing of women reporting symptoms with additional ultrasound to identify fetal 
malformations.  WHO argued against testing asymptomatic women, even in areas of high ZIKV 
incidence, as it failed on three of the Wilson & Junger screening criteria:49   poorly understood 
natural history ,  lack of effective treatment, and  low specificity of  diagnostic tests. But it is unclear 
why these criteria would not also rule out testing symptomatic women. On the other hand, the 
design of SOC and prospective study protocols alike must be sensitive to the cultural, religious, and 
medico-legal context: in some countries a confirmed diagnosis of ZIKV in pregnancy may be of little 
benefit to the mother, and could even lead to harm.50 In such circumstances protocols that go 
beyond multiple uterine  ultrasound may not be feasible.  
More critically, the WHO protocol47 made no provision for laboratory testing and follow-up of infants 
of women with confirmed or suspected ZIKV in pregnancy, unless congenital anomalies were 
present. Remarkably, positive ZIKV results in pregnancy are described as “false positives” if not 
resulting in microcephaly. WHO also recommended TORCH testing of neonates born to women with 
suspected ZIKV in pregnancy, but no tests for congenital ZIKV.51 WHO guidance may have 
discouraged some Latin American countries from adopting SOCs that would have provided 
appropriate care to families at risk, and which - as we show below - would concurrently have 
generated prospective study data on a very large scale.  
 
Prospective studies based on surveillance and SOC for Zika in pregnancy.  
During a ZIKV outbreak, pregnant women can be referred into a SOC protocol in two ways: either 
through a ZIKV surveillance system, if they have symptoms; or through repeat serological or 
virological testing offered by a maternity care provider. Once an SOC is operational, it inevitably 
generates cohorts of women with confirmed or suspected ZIKV in pregnancy.  A “prospective study” 
is therefore generated simply by carrying out SOC investigations and recording results. All the 
prospective studies published so far (Table 4) have been generated in this way.  
Equally, the same SOC protocols also generate unexposed controls groups (Control Group 2), at least 
to the extent that this is possible for ZIKV. Thus, some studies have reported outcomes in women 
who were PCR negative in pregnancy, interpretable as “No evidence of infection in pregnancy” 
(Table 4). However, detailed imaging, testing and follow-up of apparently healthy newborns born to 
women without evidence of MIP is explicitly ruled out in CDC guidelines,52 and is likely to require 
informed consent in any jurisdiction. It is at this point that a formal prospective study can go further 




their newborns. However, the identification of these infants, and ethical approval and logistics for 
follow-up, will be facilitated if their mothers are already part of a SOC protocol for ZIKV-exposed 
pregnant women. Follow-up of healthy children with no evidence of MIP raises some specific 
problems, which we return to below.  
Table 4 illustrates that prospective studies based on local SOCs are a viable alternative to 
collaborative projects funded through US or EC partners (Table 3), even in the absence of funding.16 
In the US, pregnancy outcomes in women potentially ZIKV-exposed and under the CDC protocol are 
recorded in the US Zika Pregnancy Register (USZPR). This has documented serious brain 
abnormalities with or without microcephaly in 6% to 15% of pregnancies with confirmed infection, 
with higher rates following first trimester infection.53–55  The authors acknowledge that these are 
likely to be over-estimates, as USZPR includes pregnancies in which Zika involvement was recognized 
retrospectively, following detection of anomalies on routine imaging, or at delivery.  
Such registers represent a third, and massively under-exploited way of generating prospective data 
on ZIKV in pregnancy. They can either recruit directly into prospective studies,56,57 or be  converted  
into prospective cohort studies retrospectively, by checking the dates of maternal tests relative to 
delivery, and removing mother-child pairs in which infection in pregnancy was retrospectively 
ascertained. Just such a retrospective reconstruction of a prospective cohort based on the USZPR 
was conducted in New York City,58 reporting markers of congenital infection in 11% and 7% of 
infants of mothers with “confirmed” and “probable” infection in pregnancy respectively (Table 4). 
  
Other opportunities for retrospective reconstruction of prospective studies 
SOC protocols that provide for infant testing and follow-up cannot be established immediately in the 
context of outbreaks that emerge rapidly and without warning. There will therefore always be a 
need for retrospective reconstructions. One option is to reconstruct prospective studies from 
surveillance records of pregnant women who reported symptoms and were tested.  
With hindsight, it now seems remarkable that in many countries these pregnancies were not 
referred to ZIKV-related care protocols in maternity hospitals for additional investigations and infant 
follow-up.  This should remind us that whatever protocols are in place, there may be insufficient 
resources for laboratory infrastructure and follow-up. However, this process can be carried out 
retrospectively as a review of maternity and delivery records. Consent could also be sought for 




An interesting addition to retrospective review would be to use residual samples routinely collected 
for newborn sickle cell and/or metabolic screening, as dried blood spots. Many countries in Latin 
America and the Caribbean have routine newborn screening in national, regional and hospital 
laboratories.59  Newborn dried blood spots have been tested in retrospectively reconstructed cohort 
studies of congenital infections60 but also in irreversibly anonymized studies retaining demographic 
information.61,62 Stored residual newborn dried blood spots could be tested for ZIKV RNA and IgM, 
retaining information on confirmed or suspected maternal ZIKV infection, and trimester in which 
symptoms occurred. Laboratory markers cannot be found in a proportion of congenital infection,41,42 
but studies would set a lower limit on the vertical transmission rate.  A sample of newborns of 
women with no evidence of Zika could also be included, as well as randomly selected controls whose 
mothers were not notified to surveillance.  
A second potential approach to reconstruct prospective studies post-epidemic is the use of stored 
samples collected during routine antenatal care whilst the outbreak was ongoing. These could be 
tested for markers of infection; confirmed and suspected cases, plus a sample of those with “No 
Evidence of MIP”, could again be entered into a record review of pregnancy and neonatal outcomes 
as above, with the option of obtaining consent for pediatric follow-up, and testing of stored residual 
newborn screening samples. Joint testing of linked anonymized antenatal and neonatal samples 
creates many further opportunities for large-scale reconstruction of incidence in pregnant women 
and vertical transmission, although is logistically more complex. 
These designs could be applied now to study the 2015-16 Zika outbreak, but they have a wider 
significance. There will always be a role for retrospectively reconstructed cohort studies in future 
outbreaks of pathogens that affect fetal health, especially when no clear diagnostic pathway, or 
even the pathogen, is identified until later. Such studies may be especially valuable in countries 
where medical, religious, legal or cultural constraints limit the benefit of a prospective diagnosis of 
ZIKV in pregnancy. There are logistic requirements: if conducted prospectively, studies based on 
surveillance reports require only coordination between the surveillance centre, the relevant 
laboratory and the maternity hospital.15,17,18 However, in a retrospective design, these three sets of 
patient records have to be linked. This can be done using names, addresses, and dates of birth, but 
record linkage can be greatly facilitated by having unique common identifier, such as the mother’s 
national security number, on all records, including those of the infant.  
Retrospective designs require neonatal and antenatal samples to be stored for longer, which has a 
cost. Resources could be conserved by focusing on a small number of maternity hospitals serving 




Retrospective studies including “control” mother-child pairs may also require consent, which could 
perhaps be obtained on a universal basis during an outbreak. 
 
Role of international agencies and funders in global preparedness 
Only prospective studies can fully answer the key scientific and public health questions around ZIKV 
infection in pregnancy and its consequences, ideally including an unexposed control group. We have 
argued that SOC protocols for pregnant women provide a feasible approach, allowing autonomy of 
local institutional review boards, and ensuring access to the relevant diagnostics and to locally 
trained research and nursing staff integrated within the health care system. This resolves the delays 
and barriers19 that confront prospective studies established by externally-funded researchers (ethics 
approvals, creation of data collection systems and laboratory infrastructure).  Furthermore, 
externally-originated research protocols may do little to foster global preparedness if the 
infrastructure is unsupported once the project ends.  
One of the difficulties in studying outcomes of ZIKV in pregnancy is testing and follow-up of healthy 
children, especially when maternal infection is not apparent. It is recognized that global 
preparedness demands much faster development of diagnostics,63 but the particular need for non-
invasive tests may not have been appreciated. Capillary blood samples collected by heel prick are 
well accepted, widely used with rapid diagnostic tests (RDTs) and can be dried and stored long-term. 
Oral fluid samples contain the same antibody pattern as serum and are used for measles and rubella 
case-based surveillance,64,65 for HIV RDTs,66 and extensively for virus detection by PCR. Throat swabs 
are used for diagnosis of congenital CMV.67  
We believe that global preparedness must focus more on the care of pregnant women and their 
children, with the primary task being the development of culturally sensitive SOC protocols that are 
appropriate to settings and resources available, backed up by assistance in implementing them, 
including approaches to data capture, recording and linkage. These SOCs represent de facto 
prospective studies that will answer the key research questions more rapidly than  internationally-
led research studies. Furthermore, prospective studies can be reconstructed on a very large scale, 
with appropriate filtering out of retrospectively-ascertained maternal infection, from registers 
recording outcomes under SOC. For more subtle outcomes, informed consent would be needed to 
follow-up unexposed “control” infants, but this can be built onto SOC protocols.  
Strengthened surveillance is a key component of preparedness:6 a focus on pregnancy would 
prioritize surveillance for stillbirths, neonatal mortality, congenital malformations, auditory and 




emerges with potential for congenital infection, international agencies should devise mechanisms 
for accelerated development of non-invasive diagnostics, and promote facilities for longer-term 
storage of routinely collected antenatal and neonatal samples, which can be linked to maternity and 
pediatric records. No matter how rapid the response to an emerging pathogen, retrospective studies 
based on stored samples will always be needed.  




The paper arose from discussions at the November 2017 ZIKAction consortium meeting at University 
of Florida, Gainesville, FL. AEA drafted the paper with input from all co-authors. The final decision to 
submit was taken by CDCC and CT, who co-lead the ZIKAction vertical transmission work package. CG 
is the ZIKAction principal investigator. All co-authors read, contributed to and approved the final 
version. 
 
Declaration of interests 
CT received funding from Penta Foundation and Abb Vie during the period of the study, outside the 
submitted work. All authors are members of the ZikAction consortium 
 
Acknowledgements 
This project has received funding from the European Union’s Horizon 2020 research and innovation 
programme under grant agreement No 734857. The sponsors had no role in the origination or 






Table 1. Design of a prospective vertical transmission study. The table shows cell frequency counts 
a,b…f of birth outcomes broken down by congenital infection status, presence or absence of adverse 
outcomes, and maternal infection status. The Vertical Transmission rate is estimated by 
(a+b)/(a+b+c+d). The rate of adverse outcomes conditional on congenital infection is a/(a+b).  For 
less specific adverse outcomes this can be compared with the rate of outcomes in newborns with no 
congenital infection, c/(c+d), whose mothers were infected in pregnancy (Control Group 1). An 
overall adverse event rate can be estimated, (a+c)/(a+b+c+d), pooling congenital infection and No 
congenital infection. Follow-up of births where there has been no maternal infection in pregnancy 
(MIP) represent a second control group (Control Group 2), with a rate of adverse outcomes, e/(e+f). 
In the absence of clear diagnostic criteria for congenital infection, as with ZIKV, this second control 
group is needed.  
Some cells have zeros as there can be no congenital infection without maternal infection in 
pregnancy. 
 
 Maternal Infection in Pregnancy (MIP) 
Status 





















Adverse outcomes a 0 
No Adverse outcomes b 0 
No CI 
Adverse outcomes c E 






Table 2.  Standard protocols of care for women exposed to Zika outbreaks 
State Date Provision for screening women 
potentially exposed during 
pregnancy 
Care of newborn mother 
with confirmed ZIKV in 
pregnancy 
USA  January 201648 PCR, IgM if symptomatic, 
additional U/S if asymptomatic 
Laboratory testing for 
congenital ZIKV, clinical 
follow-up 
Brazil January 201668 Testing and U/S in symptomatic Follow-up if microcephaly  
France  January 2016 69 PCR, IgM additional U/S if 
symptomatic 
Laboratory testing for 
congenital ZIKV, clinical 
follow-up 
France April 201670 PCR, IgM testing regardless of 
symptoms 
Laboratory testing, clinical 
follow-up 
WHO May 201647 Testing and U/S if symptomatic Follow-up if microcephaly  
WHO August 201651 Not applicable TORCH screen, but no tests 
for Congenital ZIKV 
Brazil November 201671 Testing and U/S if symptomatic Follow-up if symptoms of 
ZIKA in first 3 years 
USA  July 201772 3 PCR tests, additional U/S, 
regardless of symptoms 
Laboratory testing for 
congenital ZIKV, clinical 
follow-up 
Spain  April 201773 PCR, IgM and IgG regardless of 
symptoms, alongside U/S; if IgG(+) 
then PRNT-ZIKV 
Laboratory testing for 
congenital ZIKV and clinical 
follow-up for all born to 
ZIKV-infected mothers 
(probable and confirmed) 






Table 3. Protocols of four international collaborative prospective studies, funded through US or EU 
partners 
 
Study Funder Provision for screening women 
potentially exposed during 
pregnancy 
Care of newborn of mother 




Repeat serological and PCR tests Laboratory testing for 




Repeat serological tests Laboratory testing for 












Repeat PCR tests Laboratory testing for 
congenital ZIKV, clinical 
follow-up 







Table 4. Prospective studies published before April 2019: method of recruitment, cohorts followed, prevalence of adverse outcomes and of markers of 
congenital infection (CI).  
Region Recruitment Cohorts reported Adverse Outcomes, % Markers 
of CI, % 
Brazil18 Rash in pregnancy, 
dengue surveillance 
programme 
1. Confirmed MIP (n=134) 
2. No Evidence of MIP (n=73) 




Texas, USA56 Prospective USZPR 1. Confirmed or probable MIP (n=28) 





French Guiana46 Three PCR tests on all 
pregnant women 
1. Confirmed MIP (n=301) 
2. No Evidence of MIP (n=399) 




French Guiana 74 Three PCR tests on all 
pregnant women 
1. Confirmed MIP (n=291) 4% “Severe complications” 35% 
Martinique & Guadeloupe  15 ZIKV Surveillance, 
symptomatic women 
1. Confirmed MIP (n=555) 10% “Neurological and 
ocular defects” 
NR 
Colombia75 National surveillance 1. ZIKV Symptoms in pregnancy, 3rd 
trimester (n=c.570) 
0% “microcephaly <3SD or 
brain abnormalities 
NR 
New York City, USA 58 Retrospective 
reconstruction USZPR, 
1. Confirmed (n=80) 





Brazil 17 Symptoms of ZIKV in 
pregnancy 
1. Confirmed MIP (n=57) 28% “Adverse outcomes” 26% 
Barcelona57  ZIKV surveillance 
travellers 
1. Confirmed MIP (n=9) 
2. Probable MIP (n=62) 










1 Kluberg SA, Mekaru SR, McIver DJ, et al. Global capacity for emerging infectious disease 
detection, 1996–2014. Emerg Infect Dis 2016; 22: e1–9. 
2 Sands P, Mundaca-Shah C, Dzau VJ. The Neglected Dimension of Global Security — A 
Framework for Countering Infectious-Disease Crises. N Engl J Med 2016; 374: 1281–7. 
3 Oppenheim B, Gallivan M, Madhav NK, et al. Assessing global preparedness for the next 
pandemic: Development and application of an Epidemic Preparedness Index. BMJ Glob Heal 
2019; 4: 1–9. 
4 Musso D, Bossin H, Mallet HP, et al. Zika virus in French Polynesia 2013–14: anatomy of a 
completed outbreak. Lancet Infect Dis 2018; 18: e172–82. 
5 Haddad LB, Horton J, Ribner BS, Jamieson DJ. Ebola Infection in Pregnancy: A Global 
Perspective and Lessons Learned. Clin Obstet Gynecol 2018; 61: 186–96. 
6 The PREVENT Working Group. Pregnant women & vaccines against emerging epidemic 
threats: Ethics Guidance for Preparedness, Research, and Response. 2018. 
7 Roth A, Mercier A, Lepers C, et al. Concurrent outbreaks of dengue, chikungunya and zika 
virus infections null An unprecedented epidemic wave of mosquito-borne viruses in the 
Pacific 2012null2014. Eurosurveillance 2014; 19: 1–8. 
8 Campos GS, Bandeira AC, Sardi SI. Zika Virus Outbreak, Bahia, Brazil. Emerg Infect Dis 2015; 
21: 1885–6. 
9 Pan American Health Organization / World Health Organization. Zika - Epidemiological 
Update, 26 January 2017. 2017. 
10 França GVA, Schuler-Faccini L, Oliveira WK, et al. Congenital Zika virus syndrome in Brazil: a 
case series of the first 1501 livebirths with complete investigation. Lancet 2016; 388: 891–7. 
11 Calvet G, Aguiar RS, Melo ASO, et al. Detection and sequencing of Zika virus from amniotic 
fluid of fetuses with microcephaly in Brazil: a case study. Lancet Infect Dis 2016; 16: 653–60. 
12 PAHO, WHO. Epidemiological Alert: Zika virus infection. 2015. DOI:10.1111/1469-0691.12707. 
13 Gulland A. Zika virus is a global public health emergency, declares WHO. BMJ 2016; 352: i657. 
14 Wilder-Smith A, Preet R, Renhorn KE, et al. ZikaPLAN: Zika Preparedness Latin American 
Network. Glob Health Action 2017; 10: 1398485. 
15 Hoen B, Schaub B, Funk AL, et al. Pregnancy Outcomes after ZIKV Infection in French 
Territories in the Americas. N Engl J Med 2018; 378: 985–94. 
16 Pomar L, Vouga M, Lambert V, et al. Maternal-fetal transmission and adverse perinatal 
outcomes in pregnant women infected with Zika virus: Prospective cohort study in French 
Guiana. BMJ 2018; 363: k4431. 
17 Nogueira ML, Nery Júnior NRR, Estofolete CF, et al. Adverse birth outcomes associated with 
Zika virus exposure during pregnancy in São José do Rio Preto, Brazil. Clin Microbiol Infect 
2018; 24: 646–52. 
18 Brasil P, Pereira J, Moreira E, et al. Zika Virus Infection in Pregnant Women in Rio de Janeiro. 
N Engl J Med 2016; 56: 1024–5. 
19 Koopmans M, de Lamballerie X, Jaenisch T, et al. Familiar barriers still unresolved—a 
perspective on the Zika virus outbreak research response. Lancet Infect. Dis. 2019; 19: e59–
62. 
20 Stagno S, Pass RF, Cloud G, et al. Primary cytomegalovirus infection in pregnancy. Incidence, 
transmission to fetus, and clinical outcome. JAMA 1986; 256: 1904–8. 
21 Peckham CS, Coleman JC, Hurley R, Kong Shin Chin, Henderson K, Preece PM. 




Lancet 1983; 321: 1352–5. 
22 Gras L, Gilbert RE, Ades AE, Dunn DT. Effect of prenatal treatment on the risk of intracranial 
and ocular lesions in children with congenital toxoplasmosis. Int J Epidemiol 2001; 30: 1309–
13. 
23 The SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group. Effectiveness of 
prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients’ data. 
Lancet 2007; 369: 115–22. 
24 Mok JQ, Giaquinto C, De Rossi A, Grosch-Wörner I, Ades AE, Peckham CS. Infants born to 
mothers seropositive for human immunodeficiency virus. Preliminary findings from a 
multicentre European study. Lancet (London, England) 1987; 1: 1164–8. 
25 Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: 
prospective study of risk factors and timing of infection in children born to women 
seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. Bmj 1998; 317: 
437–41. 
26 Ahlfors K, Ivarsson SA, Johnsson T, Svanberg L. Primary and Secondary maternal 
cytomegalovirus infections and their relation to congenital infection: Analysis of Maternal 
Sera. Acta Pædiatrica 1982; 71: 109–13. 
27 Mandelbrot, Mayaux, Bongain, et al. Obstetric factors and mother-to-child transmission of 
human immunodeficiency virus type 1: The French perinatal cohorts. Am J Obstet Gynecol 
1996; 175: 661–7. 
28 Dunn DT, Ades AE. Estimating the HIV Vertical Transmission Rate and the Pediatric AIDS 
Incubation Period from Prospective Data AU. J Am Stat Assoc 1996; 91: 935–43. 
29 Stagno S, Pass RF, Dworsky ME, et al. Congenital Cytomegalovirus Infection: The relative 
importance of primary and recurrent maternal infection. N Engl J Med 1982; 306: 945–9. 
30 Gilbert RE, Gras L, Wallon M, Peyron F, Ades AE, Dunn DT. Effect of prenatal treatment on 
mother to child transmission of Toxoplasma gondii: Retrospective cohort study of 554 
mother-child pairs in Lyon, France. Int J Epidemiol 2001; 30: 1303–8. 
31 SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group. Effectiveness of 
prenatal treatment for congenital toxoplasmosis: A meta-analysis of individual patients’ data. 
Lancet. 2007; 62: 302–4. 
32 Preece PM, Blount JM, Glover J, Fletcher GM, Peckham CS, Griffiths PD. The consequences of 
primary cytomegalovirus infection in pregnancy. Arch Dis Child 1983; 58: 970–5. 
33 Townsend CL, Forsgren M, Ahlfors K, Ivarsson SA, Tookey PA, Peckham CS. Long-term 
outcomes of congenital cytomegalovirus infection in Sweden and the United Kingdom. Clin 
Infect Dis 2013; 56: 1232–9. 
34 Li XL, Wei HX, Zhang H, Peng HJ, Lindsay DS. A meta analysis on risks of adverse pregnancy 
outcomes in Toxoplasma gondii infection. PLoS One 2014; 9: 1–12. 
35 Paixão ES, Costa M da CN, Teixeira MG, et al. Symptomatic dengue infection during 
pregnancy and the risk of stillbirth in Brazil, 2006–12: a matched case-control study. Lancet 
Infect Dis 2017; 17: 957–64. 
36 Rijken MJ, McGready R, Boel ME, et al. Malaria in pregnancy in the Asia-Pacific region. Lancet 
Infect Dis 2012; 12: 75–88. 
37 Cardenas I, Means RE, Aldo P, et al. Viral Infection of the Placenta Leads to Fetal 
Inflammation and Sensitization to Bacterial Products Predisposing to Preterm Labor. J 
Immunol 2010; 185: 1248–57. 
38 Moore CA, Staples JE, Dobyns WB, et al. Characterizing the pattern of anomalies in congenital 




39 van der Linden V, Pessoa A, Dobyns W, et al. Description of 13 Infants Born During October 
2015–January 2016 With Congenital Zika Virus Infection Without Microcephaly at Birth — 
Brazil. Morb Mortal Wkly Rep 2016; 65: 1343–8. 
40 de Araújo TVB, Ximenes RA de A, Miranda-Filho D de B, et al. Association between 
microcephaly, Zika virus infection, and other risk factors in Brazil: Final report of a case-
control study. Lancet Infect Dis 2017; 3099: 1–9. 
41 Rodó C, Suy A, Sulleiro E, et al. In utero negativization of Zika virus in a foetus with serious 
central nervous system abnormalities. Clin Microbiol Infect 2018; 24: 549.e1-549.e3. 
42 Schaub B, Vouga M, Najioullah F, et al. Analysis of blood from Zika virus-infected fetuses: a 
prospective case series. Lancet Infect Dis 2017; 17: 520–7. 
43 Paz-Bailey G, Rosenberg ES, Doyle K, et al. Persistence of Zika Virus in Body Fluids — Final 
Report. N Engl J Med 2018; : NEJMoa1613108. 
44 Rabe IB, Staples JE, Villanueva J, et al. Interim Guidance for Interpretation of Zika Virus 
Antibody Test Results. MMWR Morb Mortal Wkly Rep 2016; 65: 543–6. 
45 Centers for Disease Control and Prevention. Prolonged IgM Antibody Response in People 
Infected with Zika Virus : Implications for Interpreting Serologic Testing Results for Pregnant. 
2017; : 5–7. 
46 Pomar L, Malinger G, Benoist G, et al. Association between Zika virus and fetopathy: a 
prospective cohort study in French Guiana. Ultrasound Obstet Gynecol 2017; 49: 729–36. 
47 World Health Organization. Pregnancy management in the context of Zika virus infection: 
Interim guidance update. 13 May 2016. 2016. 
48 Petersen EE, Meaney-Delman, D, Ellington SR, et al. Interim Guidelines for Pregnant Women 
During a Zika Virus Outbreak — United States, 2016. MMWR Morb Mortal Wkly Rep 2016; 65: 
1–4. 
49 Wilson JMG, Jugner G. Principles and Practice of Screening for Disease. Geneva, 1968 
DOI:10.3390/ijns3030023. 
50 Roa M. Zika virus outbreak: Reproductive health and rights in Latin America. Lancet 2016; 
387: 843. 
51 World Health Organization. Screening, assessment and management of neonates and infants 
with complications associated with Zika virus exposure in utero. 2016 
DOI:http://apps.who.int/iris/bitstream/10665/204475/1/WHO_ZIKV_MOC_16.3_eng.pdf?ua
=1. 
52 Adebanjo T, Godfred-Cato S, Viens L, et al. Update: Interim Guidance for the Diagnosis, 
Evaluation, and Management of Infants with Possible Congenital Zika Virus Infection — 
United States, October 2017. MMWR Morb Mortal Wkly Rep 2017; 66: 1089–99. 
53 Honein MA, Dawson AL, Petersen EE, et al. Birth defects among fetuses and infants of US 
women with evidence of possible zika virus infection during pregnancy. JAMA - J Am Med 
Assoc 2017; 317: 59–68. 
54 Reynolds M, Jones A, Petersen E, Lee E, Rice M, Bingham A. Vital Signs: Update on Zika Virus–
Associated Birth Defects and Evaluation of All U.S. Infants with Congenital Zika Virus Exposure 
— U.S. Zika Pregnancy Registry, 2016. Morb Mortal Wkly Rep 2017; 66: 366–73. 
55 Shapiro-Mendoza CK, Rice ME, Galang RR, et al. Pregnancy Outcomes After Maternal Zika 
Virus Infection During Pregnancy — U.S. Territories, January 1, 2016–April 25, 2017. MMWR 
Morb Mortal Wkly Rep 2017; 66: 615–21. 
56 Adhikari EH, Nelson DB, Johnson KA, et al. Infant outcomes among women with Zika virus 
infection during pregnancy: results of a large prenatal Zika screening program. Am J Obstet 




57 Rodó C, Suy A, Sulleiro E, et al. Pregnancy outcomes after maternal Zika virus infection in a 
non-endemic region: prospective cohort study. Clin Microbiol Infect 2019. 
DOI:10.1016/j.cmi.2019.02.008. 
58 Conners EE, Lee EH, Thompson CN, et al. Zika Virus Infection Among PregnantWomen and 
Their Neonates in NewYork City, January 2016–June 2017. Obs Gynecol 2018; 132: 487–95. 
59 Therrell BL, Padilla CD, Loeber JG, et al. Current status of newborn screening worldwide: 
2015. Semin Perinatol 2015; 39: 171–87. 
60 Korndewal MJ, Vossen ACTM, Cremer J, et al. Disease burden of congenital cytomegalovirus 
infection at school entry age: Study design, participation rate and birth prevalence. Epidemiol 
Infect 2016; 144: 1520–7. 
61 Ades AE, Walker J, Botting B, Parker S, Cubitt D, Jones R. Effect of the worldwide epidemic on 
HIV prevalence in the United Kingdom: Record linkage in anonymous neonatal 
seroprevalence surveys. AIDS 1999; 13: 2437–43. 
62 Carnicer-Pont D, Montoliu A, Marín JL, et al. Twenty years trends and socio-demographic 
characteristics of HIV prevalence in women giving birth in Catalonia (Spain). Gac Sanit 2015; 
29: 347–52. 
63 Peeling RW, Murtagh M, Olliaro PL. Epidemic preparedness: why is there a need to accelerate 
the development of diagnostics? Lancet Infect Dis 2018; 3099: 1–7. 
64 Manikkavasagan G, Bukasa A, Brown KE, Cohen BJ, Ramsay ME. Oral fluid testing during 10 
years of rubella elimination, England and Wales. Emerg Infect Dis 2010; 16: 1532–8. 
65 Jin L, Vyse A, Brown DWG. The role of RT-PCR assay of oral fluid for diagnosis and surveillance 
of measles, mumps and rubella. Bull. World Health Organ. 2002; 80: 76–7. 
66 Belete W, Deressa T, Feleke A, et al. Evaluation of diagnostic performance of noninvasive HIV 
self-testing kit using oral fluid in Addis Ababa, Ethiopia: A facility-based cross-sectional study. 
PLoS One 2019; 14: 1–10. 
67 Roth DAE, Lubin D, Kuint J, et al. Contribution of targeted saliva screening for congenital 
CMV-related hearing loss in newborns who fail hearing screening. Arch Dis Child Fetal 
Neonatal Ed 2017; 102: F519–24. 
68 Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Protocolo de atenção à saúde e 
resposta à ocorrência de microcefalia relacionada à  infecção pelo vírus Zika. 2016. 
69 Haut Conseil de la Santé Publique. Avis relatif à l’actualisation de l’avis du HCSP du 28 juillet 
2015 relatif à la prise en charge médicale des personnes atteintes par le virus Zika. 2016; : 1–
27. 
70 Collège National de Gynécologues at Obstétricens Français. Virus ZIKA Et femme enceinte ou 
en âge de procréer. 2014; : 1–6. 
71 BRASIL, Ministério da Saúde. Diretrizes de estimulação precoce Crianças de zero a 3 anos com 
Atraso no Desenvolvimento Neuropsicomotor Decorrente de Microcefalia. Ministério da 
Saúde Secr Atenção à Saúde 2016; : 123. 
72 Oduyebo T, Polen KD, Walke HT, et al. Update: Interim Guidance for Health Care Providers 
Caring for Pregnant Women with Possible Zika Virus Exposure — United States (Including U.S. 
Territories), July 2017. MMWR Morb Mortal Wkly Rep 2017; 66: 781–93. 
73 Subdirecció General de Vigilància i Resposta a Emergències de Salut Pública. Generalitat de 
Catalunya. Protocol d’actuació davant de casos de febre vírica de Zika en l’àmbit obstètric i 
pediàtric de Catalunya. Barcelona Agència Salut Pública Catalunya 2016. 
74 Pomar L, Vouga M, Lambert V, et al. Maternal-fetal transmission and adverse perinatal 
outcomes in pregnant women infected with Zika virus: Prospective cohort study in French 




75 Pacheco O, Beltrán M, Nelson CA, et al. Zika Virus Disease in Colombia — Preliminary Report. 












Please insert the relevant text under the subheadings below. A completed form must be signed by all authors. Please note that we will 
accept hand-signed and electronic (typewritten) signatures. Please complete multiple forms if necessary, and upload the signed copy with 




For research articles only:
I irrevocably authorise and grant my full consent to the corresponding author of the manuscript to: (1) enter into an exclusive publishing 
agreement with Elsevier on my behalf, in the relevant form set out at www.elsevier.com/copyright; and (2) unless I am a US government 
employee, to transfer my copyright or grant an exclusive license of rights to Elsevier as part of that publishing agreement, effective on 
acceptance of the article for publication.  If the article is a work made for hire, I am authorized to confirm this on behalf of my employer.  I 
agree that the copyright status selected by the corresponding author for the article shall apply and that this agreement is subject to the 
governing law of England and Wales.
Does your manuscript have a reference number? No q    Yes q    If yes, enter number here: 
Does your manuscript have a handling editor? No q    Yes q    If yes, enter name here: 
Authors’ contributions
Please insert here the contribution each author made to the manuscript—eg, literature search, figures, study design, data collection, data 
analysis, data interpretation, writing etc. If all authors contributed equally, please state this.  The information provided here must match the 
contributors’ statement in the manuscript.
Table
      Researching Zika in pregnancy: lessons for global preparedness
          A E Ades
           Personal view
19 - 00512
     Sally Hargreaves
Role of the funding source
Please disclose any funding sources and their role, if any, in the writing of the manuscript or the decision to submit it for publication. 
Examples of involvement include: data collection, analysis, or interpretation; trial design; patient recruitment; or any aspect pertinent to 
the study. Please also comment whether you have been paid to write this article by a pharmaceutical company or other agency. If you are 
the corresponding author, please indicate if you had full access to all the data in the study and had final responsibility for the decision to 
submit for publication. The information provided here must match the role of the funding source statement in the manuscript.
Conflicts of interest
Please complete the ICMJE conflict of interest form, which is available at http://www.thelancet.com/for-authors/forms#icmje-coi. Please 
ensure that a conflict of interest statement is included at the end of the manuscript, which matches what is declared on the ICMJE conflict 
of interest form.
Patient consent (if applicable) - completion of this section is mandatory for Clinical Pictures, and Grand Round.
Please sign below to confirm that all necessary consents required by applicable law from any relevant patient, research participant, and/or 
other individual whose information is included in the article have been obtained in writing. The signed consent form(s) should be 
retained by the corresponding author and NOT sent to The Lancet Infectious Diseases.
I agree with: the plan to submit to The Lancet Infectious Diseases; the contents of the manuscript; to being listed as an author; and 
to the conflicts of interest statement as summarised. I have had access to all the data in the study (for original research articles) 
and accept responsibility for its validity.
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Corresponding author declaration
I                 [Signature]                 , the corresponding author of this manuscript, certify that the contributors’ and conflicts of interest 
statements included in this paper are correct and have been approved by all co-authors.





Please insert the relevant text under the subheadings below. A completed form must be signed by all authors. Please note that we will 
accept hand-signed and electronic (typewritten) signatures. Please complete multiple forms if necessary, and upload the signed copy with 




For research articles only:
I irrevocably authorise and grant my full consent to the corresponding author of the manuscript to: (1) enter into an exclusive publishing 
agreement with Elsevier on my behalf, in the relevant form set out at www.elsevier.com/copyright; and (2) unless I am a US government 
employee, to transfer my copyright or grant an exclusive license of rights to Elsevier as part of that publishing agreement, effective on 
acceptance of the article for publication.  If the article is a work made for hire, I am authorized to confirm this on behalf of my employer.  I 
agree that the copyright status selected by the corresponding author for the article shall apply and that this agreement is subject to the 
governing law of England and Wales.
Does your manuscript have a reference number? No q    Yes q    If yes, enter number here: 
Does your manuscript have a handling editor? No q    Yes q    If yes, enter name here: 
Authors’ contributions
Please insert here the contribution each author made to the manuscript—eg, literature search, figures, study design, data collection, data 
analysis, data interpretation, writing etc. If all authors contributed equally, please state this.  The information provided here must match the 
contributors’ statement in the manuscript.
Table
      Researching Zika in pregnancy: lessons for global preparedness
          A E Ades
           Personal view
19 - 00512
     Sally Hargreaves
Role of the funding source
Please disclose any funding sources and their role, if any, in the writing of the manuscript or the decision to submit it for publication. 
Examples of involvement include: data collection, analysis, or interpretation; trial design; patient recruitment; or any aspect pertinent to 
the study. Please also comment whether you have been paid to write this article by a pharmaceutical company or other agency. If you are 
the corresponding author, please indicate if you had full access to all the data in the study and had final responsibility for the decision to 
submit for publication. The information provided here must match the role of the funding source statement in the manuscript.
Conflicts of interest
Please complete the ICMJE conflict of interest form, which is available at http://www.thelancet.com/for-authors/forms#icmje-coi. Please 
ensure that a conflict of interest statement is included at the end of the manuscript, which matches what is declared on the ICMJE conflict 
of interest form.
Patient consent (if applicable) - completion of this section is mandatory for Clinical Pictures, and Grand Round.
Please sign below to confirm that all necessary consents required by applicable law from any relevant patient, research participant, and/or 
other individual whose information is included in the article have been obtained in writing. The signed consent form(s) should be 
retained by the corresponding author and NOT sent to The Lancet Infectious Diseases.
I agree with: the plan to submit to The Lancet Infectious Diseases; the contents of the manuscript; to being listed as an author; and 
to the conflicts of interest statement as summarised. I have had access to all the data in the study (for original research articles) 
and accept responsibility for its validity.
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Corresponding author declaration
I                 [Signature]                 , the corresponding author of this manuscript, certify that the contributors’ and conflicts of interest 
statements included in this paper are correct and have been approved by all co-authors.
The funding source had no role in the drafting of this paper or the decision to submit
Professor J. Glenn Morris MD
J. Glenn 
Morris, Jr
Digitally signed by J. Glenn 
Morris, Jr 
Date: 2019.09.30 12:27:06 
-04'00'
Author statements
Please insert the relevant text under the subheadings below. A completed form must be signed by all authors. Please note that we will 
accept hand-signed and electronic (typewritten) signatures. Please complete multiple forms if necessary, and upload the signed copy with 




For research articles only:
I irrevocably authorise and grant my full consent to the corresponding author of the manuscript to: (1) enter into an exclusive publishing 
agreement with Elsevier on my behalf, in the relevant form set out at www.elsevier.com/copyright; and (2) unless I am a US government 
employee, to transfer my copyright or grant an exclusive license of rights to Elsevier as part of that publishing agreement, effective on 
acceptance of the article for publication.  If the article is a work made for hire, I am authorized to confirm this on behalf of my employer.  I 
agree that the copyright status selected by the corresponding author for the article shall apply and that this agreement is subject to the 
governing law of England and Wales.
Does your manuscript have a reference number? No q    Yes q    If yes, enter number here: 
Does your manuscript have a handling editor? No q    Yes q    If yes, enter name here: 
Authors’ contributions
Please insert here the contribution each author made to the manuscript—eg, literature search, figures, study design, data collection, data 
analysis, data interpretation, writing etc. If all authors contributed equally, please state this.  The information provided here must match the 
contributors’ statement in the manuscript.
Table
      Researching Zika in pregnancy: lessons for global preparedness
          A E Ades
           Personal view
19 - 00512
     Sally Hargreaves
CT contributed to literature search and drafting of the manuscript.
Role of the funding source
Please disclose any funding sources and their role, if any, in the writing of the manuscript or the decision to submit it for publication. 
Examples of involvement include: data collection, analysis, or interpretation; trial design; patient recruitment; or any aspect pertinent to 
the study. Please also comment whether you have been paid to write this article by a pharmaceutical company or other agency. If you are 
the corresponding author, please indicate if you had full access to all the data in the study and had final responsibility for the decision to 
submit for publication. The information provided here must match the role of the funding source statement in the manuscript.
Conflicts of interest
Please complete the ICMJE conflict of interest form, which is available at http://www.thelancet.com/for-authors/forms#icmje-coi. Please 
ensure that a conflict of interest statement is included at the end of the manuscript, which matches what is declared on the ICMJE conflict 
of interest form.
Patient consent (if applicable) - completion of this section is mandatory for Clinical Pictures, and Grand Round.
Please sign below to confirm that all necessary consents required by applicable law from any relevant patient, research participant, and/or 
other individual whose information is included in the article have been obtained in writing. The signed consent form(s) should be 
retained by the corresponding author and NOT sent to The Lancet Infectious Diseases.
I agree with: the plan to submit to The Lancet Infectious Diseases; the contents of the manuscript; to being listed as an author; and 
to the conflicts of interest statement as summarised. I have had access to all the data in the study (for original research articles) 
and accept responsibility for its validity.
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Title and name:  Highest degree:   Signature:  .............................................  Date: 
Corresponding author declaration
I                 [Signature]                 , the corresponding author of this manuscript, certify that the contributors’ and conflicts of interest 
statements included in this paper are correct and have been approved by all co-authors.
The funding source had no role in the drafting of this paper or the decision to submit
Prof Claire Thorne PhD Claire Thorne
Digitally signed by Claire 
Thorne 





If this message is not eventually replaced by the proper contents of the document, your PDF 
viewer may not be able to display this type of document. 
  
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by 
visiting  http://www.adobe.com/go/reader_download. 
  
For more assistance with Adobe Reader visit  http://www.adobe.com/go/acrreader. 
  
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark 





If this message is not eventually replaced by the proper contents of the document, your PDF 
viewer may not be able to display this type of document. 
  
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by 
visiting  http://www.adobe.com/go/reader_download. 
  
For more assistance with Adobe Reader visit  http://www.adobe.com/go/acrreader. 
  
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark 
of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other 
countries.
Table




The purpose of this form is to provide readers of your manuscript with information about your other interests that could 
influence how they receive and understand your work. The form is designed to be completed electronically and stored 
electronically.  It contains programming that allows appropriate data display.  Each author should submit a separate 
form and is responsible for the accuracy and completeness of the submitted information.  The form is in six parts. 
              Identifying information.   
            The work under consideration for publication.  
This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the 
work itself, from the initial conception and planning to the present. The requested information is about resources that you received, 
either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work 
without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that 
pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds 
from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check 
"Yes".   
          Relevant financial activities outside the submitted work.   
This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that 
give the appearance of potentially influencing, what you wrote in the submitted work.  You should disclose interactions with ANY entity 
that could be considered broadly relevant to the work.  For example, if your article is about testing an epidermal growth factor receptor 
(EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer 
in general, not just in the area of EGFR or lung cancer. 
Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to 
submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the 
entity that sponsored the research.  Please note that your interactions with the work's sponsor that are outside the submitted work 
should also be listed here.  If there is any question, it is usually better to disclose a relationship than not to do so.  
 For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be 
perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be 
perceived to have a financial stake in the outcome.  Public funding sources, such as government agencies, charitable foundations or 
academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved 
and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.  
            Intellectual Property.  
This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties. 
Relationships not covered above.  
Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of 








Other: Anything not covered under the previous three boxes  
Pending:  The patent has been filed but not issued  
Issued:  The patent has been issued by the agency   
Licensed: The patent has been licensed to an entity, whether 
earning royalties or not 
Royalties: Funds are coming in to you or your institution due to your 
patent
Entity: government agency, foundation, commercial sponsor, 
academic institution, etc.  
Grant:  A grant from an entity, generally [but not always] paid to your 
organization 
Personal Fees: Monies paid to you for services rendered, generally 
honoraria, royalties, or fees for consulting , lectures, speakers bureaus, 
expert testimony, employment, or other affiliations  
Non-Financial Support: Examples include drugs/equipment 
supplied by the entity, travel paid by the entity, writing assistance, 
administrative support, etc.
Table
ICMJE Form for Disclosure of Potential Conflicts of Interest 
2Lang
 Identifying Information Section 1.
1.  Given Name (First Name)
Daniel
2.  Surname (Last Name) 
Lang




 A. E. Ades
5.  Manuscript Title
Researching Zika in pregnancy: lessons for global awareness
6.  Manuscript Identifying Number (if you know it)
19 -  00512
The Work Under Consideration for PublicationSection 2.
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for 
any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, 
statistical analysis, etc.)?
Are there any relevant conflicts of interest? Yes No✔
            
Relevant financial activities outside the submitted work.Section 3. 
Are there any relevant conflicts of interest? Yes No✔
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount 
of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by 
clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication.
            
Intellectual Property -- Patents & CopyrightsSection 4. 
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No✔
ICMJE Form for Disclosure of Potential Conflicts of Interest 
3Lang
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of 
potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):✔
No other relationships/conditions/circumstances that present a potential conflict of interest 
 Relationships not covered aboveSection 5.
All authors have received funding through the ZIKAction consortium
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. 
On occasion, journals may ask authors to disclose further information about reported relationships. 
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box 
below.
Disclosure StatementSection 6.
Dr. Lang reports  and All authors have received funding through the ZIKAction consortium.
Evaluation and Feedback
Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.
Please wait... 
  
If this message is not eventually replaced by the proper contents of the document, your PDF 
viewer may not be able to display this type of document. 
  
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by 
visiting  http://www.adobe.com/go/reader_download. 
  
For more assistance with Adobe Reader visit  http://www.adobe.com/go/acrreader. 
  
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark 





If this message is not eventually replaced by the proper contents of the document, your PDF 
viewer may not be able to display this type of document. 
  
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by 
visiting  http://www.adobe.com/go/reader_download. 
  
For more assistance with Adobe Reader visit  http://www.adobe.com/go/acrreader. 
  
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark 





If this message is not eventually replaced by the proper contents of the document, your PDF 
viewer may not be able to display this type of document. 
  
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by 
visiting  http://www.adobe.com/go/reader_download. 
  
For more assistance with Adobe Reader visit  http://www.adobe.com/go/acrreader. 
  
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark 





If this message is not eventually replaced by the proper contents of the document, your PDF 
viewer may not be able to display this type of document. 
  
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by 
visiting  http://www.adobe.com/go/reader_download. 
  
For more assistance with Adobe Reader visit  http://www.adobe.com/go/acrreader. 
  
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark 





If this message is not eventually replaced by the proper contents of the document, your PDF 
viewer may not be able to display this type of document. 
  
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by 
visiting  http://www.adobe.com/go/reader_download. 
  
For more assistance with Adobe Reader visit  http://www.adobe.com/go/acrreader. 
  
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark 





If this message is not eventually replaced by the proper contents of the document, your PDF 
viewer may not be able to display this type of document. 
  
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by 
visiting  http://www.adobe.com/go/reader_download. 
  
For more assistance with Adobe Reader visit  http://www.adobe.com/go/acrreader. 
  
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark 
of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other 
countries.
Table
To Whom It May Concern, 
 
This is to confirm that I consent to my name appearing in the acknowledgments section of the 
“Researching Zika in pregnancy: lessons for global preparedness” research article, submitted to 
Lancet ID by AE Ades. 
 
Yours Faithfully, 
Thomas Byrne 
 
 
 
 
 
28.11.2019 
Table
